Adding Pembrolizumab to Chemotherapy Increases Pathological Complete Response, Improves Residual Cancer Burden in Early-Stage, High-Risk ER+/HER2– Breast Cancer

pCR rates improve regardless of whether patients received full chemotherapy doses.

Related Keywords

Dallas ,Texas ,United States ,Baylor University ,China ,Joyce Oshaughnessy ,Baylor University Medical Center ,Breast Cancer Research Program ,Antonio Breast Cancer Symposium ,Joyceo Shaughnessy ,Celebrating Women Chair ,Breast Cancer Research ,Baylor Charles ,Cancer Center ,Texas Oncology ,Eastern Europe ,